T ertiary lymphoid organs (TLOs) are structures that resemble lymph nodes that can be found in chronically inflamed tissues in a number of inflammatory conditions. TLOs can host ongoing immune responses that can potentially contribute to disease pathogenesis. The development of TLOs has been thought in large part to recapitulate the development of secondary lymphoid organs, but the regulation of TLO development has not been well understood. In a recent article in Nature Immunology, Troy Randall and colleagues 1 identify IL-17, a cytokine that contributes to the pathogenesis of a number of inflammatory diseases, as a novel critical player in TLO formation in inflamed lungs.
TLOs can be found in the joints of patients with rheumatoid arthritis, in the inflamed salivary glands of patients with Sjogren's syndrome, in the meninges of patients with multiple sclerosis, and in the lungs of patients with pulmonary inflammation or infection. In the lungs, induced bronchus-associated lymphoid tissues (iBALTs) are TLOs that are located along the small airways. They have distinct T-and B-cell zones. They also have other lymph node-like structures, including the following: follicular dendritic cells, which display antigen to B cells; high endothelial venules, which traffic lymphocytes and other immune cells from the bloodstream into the TLO; and lymphatics, which transport tissue dendritic cells into the TLO. Functionally, TLOs are sites of immune activity, containing germinal centers, plasma cells and effector T cells, and iBALTs may act as a reservoir for T and B cells that respond rapidly to secondary challenges. 2 Understanding the regulation of iBALT formation, therefore, may lead to new therapeutic avenues for the control of pulmonary infection and inflammation.
Lymph nodes originate as mesenchymal condensations along veins, and their development involves interactions of hematopoietic lymphoid tissue inducers with mesenchymal lymphoid tissue organizers. The CXCL13-, MADCAM-, ICAM-and VCAM-expressing lymphoid tissue organizers recruit CD4 1 CD3 2 lymphoid tissue inducers. Lymphoid tissue inducers express soluble and membrane-bound lymphotoxin, which induces further upregulation of chemoattractants and adhesion molecules on the lymphotoxin receptor-expressing lymphoid tissue organizers. This positive feedback loop results in the recruitment of immune cells to populate the nascent lymph node and the development of other features such as high endothelial venules. IL-17 has been found to be expressed by lymphoid tissue inducers in the adult spleen and fetal tissue, but a role in secondary lymphoid organ (SLO) development has not been identified (reviewed in Ref. 3) . In this study, Randall and colleagues study iBALTs that are induced by neonatal exposure to lipopolysaccharide for 10 days. Although these iBALTs depend on lymphotoxin for their organization and the development of high endothelial venules and follicular dendritic cells, these iBALTs differ from secondary lymphoid organs and from some other TLOs in that they are not dependent on lymphoid tissue inducers Instead, they show that IL-17A is elevated in the neonatal period, that IL-17A-or IL-17R-deficient mice develop fewer and smaller iBALTs, and that inhibition of IL-17 with blocking antibodies just prior to iBALT development attenuates iBALT formation. T cells are the main producers of IL-17 and are necessary for iBALT development, and transfer of T cells rescues the phenomenon in IL-17-deficient mice.
1 These results suggest that T cell-derived IL-17 is a key contributor to iBALT formation in this model. This finding is significant in several ways. First, IL-17A-deficient mice do not have described lymph node defects, suggesting that IL-17A may be unique to the inflammatory conditions that foster TLO development. Second, IL-17 and Th17 effector cells have been implicated in the pathogenesis of a number of inflammatory conditions, including rheumatoid arthritis, multiple sclerosis and asthma, 4 and this finding linking the inflammatory effector mechanism with a characteristic of chronic inflammation is both a novel role for IL-17 and a novel mechanism by which a TLO is formed. Third, the authors show that IL-17-expressing T follicular helper cells are better at inducing iBALTs than Th17-polarized cells. This raises the interesting possibility that IL-17-expressing T follicular helper cells, in addition to promoting germinal center responses, are also contributing to the regulation of lymphoid tissue structures.
How does IL-17 promote iBALT formation? The authors show that the homeostatic lymphoid tissue chemokines CXCL13, CCL19 and CCL21a are necessary for iBALT formation, that IL-17-or IL-17R-deficient mice are deficient in CXCL13 and CCL19, and that IL-17A added directly to cultured pulmonary fibroblasts can induce their expression of CXCL13 and CCL19.
1 Thus, in this system, the T cells and IL-17 are somewhat equivalent to lymphoid tissue inducers and lymphotoxin in lymph node development, and the pulmonary fibroblasts are equivalent to stromal organizers. That the investigators could only induce iBALT formation with lipopolysaccharide during a specific neonatal window raises some questions about the generalizability of their proposed mechanism, but that IL-17 could induce fibroblast expression of chemokines suggests that this effect is not unique to a neonatal tissue environment. Given the role of IL-17 in a number of conditions and the presence of TLOs in at least some of those conditions, one wonders whether a similar T cell-IL-17-fibroblast axis might contribute to TLO formation in inflamed joints or salivary glands.
In addition to identifying a new molecular mechanism for TLO development, the authors also show that neonatal exposure to lipopolysaccharide is necessary for iBALT formation upon subsequent exposure as an adult. Whether the adult iBALTs reflect expansion of persistent neonatal iBALTs or whether they represent new iBALT formation in a susceptible host is not clear, but this finding raises questions about the implications for exposure to inflammatory stimuli in the human neonate. Infections and meconium inhalation are some of the factors that can cause pulmonary inflammation in neonates-do these inflammatory stimuli permit the development of iBALTs or other TLOs upon inflammation later in life? If these TLOs are indeed pathogenic, does neonatal exposure to inflammation and upregulation of IL-17 create a host that is more likely to be affected by chronic inflammatory diseases? These types of questions are difficult to address clinically, but understanding how childhood exposures impact on later health may help to identify susceptible individuals. Taken together, the findings of Randall and colleagues spur us to reconceptualize the link between inflammation and TLOs and raise interesting questions about the link between childhood and adult health.
